Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Beta Bionics (BBNX) EBIT (2024 - 2025)

Beta Bionics (BBNX) has disclosed EBIT for 2 consecutive years, with -$16.1 million as the latest value for Q4 2025.

  • Quarterly EBIT fell 23.68% to -$16.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$71.7 million through Dec 2025, down 58.41% year-over-year, with the annual reading at -$71.7 million for FY2025, 58.41% down from the prior year.
  • EBIT hit -$16.1 million in Q4 2025 for Beta Bionics, up from -$17.0 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of -$9.5 million in Q1 2024 to a low of -$19.9 million in Q2 2025.